Sangamo Therapeutics said the Food and Drug Administration has cleared its investigational new drug application for its ST-400 treatment for intractable pain due to idiopathic small fiber neuropathy.

Excess cholesterol is known to form artery-clogging plaques that can lead to stroke, arterial disease, heart attack, and more, making it the focus of many heart health campaigns.

The ASIST study will assess the safety and efficacy of BXQ-350 plus SOC, modified FOLFOX7 (mFOLFOX7) and bevacizumab, in patients with newly diagnosed mCRC. The study is also evaluating whether the ...

A recent study from the Federal University of São Paulo (UNIFESP) has found that using infrared light along with regular ...

CMTA strengthens its role as the leading force in comprehensive CMT research, forging a new strategic alliance with the ...

At two upcoming events on rare disease clinical trials and data management, experts will dissect the latest trends and ...

Researchers have developed a non-addictive painkiller that remains inactive until it reaches sites of chronic pain. Instead of dulling the nerves that send the pain signals like other analgesics, this ...

Rather than merely masking pain signals like conventional analgesics, this new medication directly ... and diabetic ...

The Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its ...

After an investigation, the agency concluded that a case of muscle weakness in one of Novavax’s trials was actually ALS and ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & Nasdaq: ARGX) today announced that China’s National Medical Products Administrat ...